Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Aschner, P.; Kipnes, M.S.; Lunceford, J.K.; Sanchez, M.; Mickel, C.; Williams-Herman, D.E.; Williams-Herman, D.E.
    Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes (2006), Diabetes Care, 29, 2632-2637.
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
sitagliptin in a 24-week study, once-daily sitagliptin monotherapy improves glycemic control in the fasting and postprandial states, improves measures of beta-cell function, and is well tolerated in patients with type 2 diabetes Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
patients with type 2 diabetes
-

Synonyms

Synonyms Comment Organism
dipeptidyl peptidase-4
-
Homo sapiens